CDEK by Data4ThePeople
Sign in Sign up
← All drugs Report issue

carotuximab

mAbexperimental

Carotuximab (INN) (TRC-105) is a chimeric monoclonal antibody designed for the treatment of cancer. — Wikipedia

Clinical trial activity

28 trials · 13 clinical orgs · 0 marketing orgs

Phase 1
16
Phase 2
22
Phase 3
1
Phase 4
0

Earliest trial started Dec 1, 2007 (NCT00582985)

Timeline

2000s

  1. Jan 1, 2007

    Earliest Phase 1 Sponsor(trial)

2010s

  1. Jan 1, 2011

    Earliest Phase 2 Sponsor(trial)

  2. Jan 1, 2017

    Earliest Phase 3 Sponsor(trial)

Indications

Studied for

Mechanism of action

  • EndoglinINHIBITOR

    ENG inhibitor

    Induces antibody-dependent cellular cytotoxicity (ADCC) and apoptosis of CD105 (Endoglin)-positive tumour cells.

Chemistry & pharmacology

Chirality
Single Stereoisomer
Inorganic
No
Polymer
No
Multi-specific
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • carotuximab
  • de-122
  • trc105
  • trc-105

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT05401110Phase 1Dec 14, 2023Cedars-Sinai Medical Center, Kairos XR
NCT05534646Phase 2Nov 30, 2022Cedars-Sinai Medical Center, Kairos XR
NCT03418324Phase 2Mar 5, 2018Cedars-Sinai Medical Center
NCT03211234Phase 2Jul 5, 2017Santen Inc.
NCT03181308Phase 1Jul 1, 2017Tracon Pharmaceuticals Inc.
NCT02979899Phase 3Feb 13, 2017Tracon Pharmaceuticals Inc.
NCT02664961Phase 2Mar 1, 2016Tracon Pharmaceuticals Inc.
NCT02520063Phase 1/Phase 2 (Phase 2)Feb 1, 2016Novartis, Tracon Pharmaceuticals Inc., University of Alabama, Birmingham
NCT02560779Phase 1/Phase 2 (Phase 2)Jan 1, 2016Tracon Pharmaceuticals Inc.
NCT02429843Phase 1Jan 1, 2016Tracon Pharmaceuticals Inc., University of Alabama, Birmingham
NCT03780010Phase 1Sep 30, 2015Tracon Pharmaceuticals Inc., University of Alabama, Birmingham
NCT02555306Phase 1/Phase 2 (Phase 2)Sep 16, 2015Santen Inc.
NCT02396511Phase 2Jan 1, 2015Tracon Pharmaceuticals Inc.
NCT01975519Phase 1/Phase 2 (Phase 2)Dec 1, 2013Tracon Pharmaceuticals Inc.
NCT01806064Phase 1/Phase 2 (Phase 2)Mar 1, 2013Tracon Pharmaceuticals Inc.
NCT01778530Phase 2Dec 1, 2012National Cancer Institute (NCI), National Institutes of Health (NIH)
NCT01648348Phase 1/Phase 2 (Phase 2)Nov 1, 2012National Cancer Institute (NCI)
NCT01727089Phase 2Nov 1, 2012City of Hope National Medical Center, National Cancer Institute (NCI)
NCT01564914Phase 2May 1, 2012Case Western Reserve University, Tracon Pharmaceuticals Inc., University of Rochester
NCT01381861Phase 2Jul 1, 2011Tracon Pharmaceuticals Inc.
Showing 20 of 28 trials
Page 1 / 2

Organizations

Research & Development (13)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Tracon Pharmaceuticals Inc.For profit161432007
National Cancer Institute (NCI)Government7712010
National Institutes of Health (NIH)Government4012010
Cedars-Sinai Medical CenterAcademic/Hospital3322018
University of Alabama, BirminghamAcademic/Hospital3222015
Kairos XRFor profit2022022
Santen Inc.For profit2212015
Case Western Reserve UniversityAcademic/Hospital1012012
City of Hope National Medical CenterAcademic/Hospital1012012
Department of DefenseGovernment1012011
NovartisFor profit1012016
State University of New York, BuffaloAcademic/Hospital1012011
University of RochesterAcademic/Hospital1012012
13 organizations
Page 1 / 1